[REVISION HISTORY]

Brazil expands public cancer screening

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-10 15:37 UTC → 2026-08-12 12:42 UTC · added ~~removed~~

In July 2026, Brazil announced new guidelines prioritizing molecular HPV testing with self-collection to replace the Pap smear, aiming to increase participation and reduce disparities in cervical cancer screening. Implementation has already begun in locations such as Piancó, Paraíba, where DNA-HPV molecular tests are being offered to women aged 25–64. To support these efforts, legislative proposal Bill 969/26 has been introduced, seeking to make the HPV vaccine mandatory and formalize the Unified Health System’s (SUS) transition to molecular testing as the primary screening method. In the state of Bahia, a new phase of screening using molecular DNA-HPV testing is also being implemented. These updates follow 2025 guidelines from the National Cancer Institute (INCA) and are intended to address high incidence rates and health inequalities, particularly in the North and Northeast regions. Proponents suggest that modernizing screening and expanding vaccination coverage will improve early detection, reduce mortality, and provide long-term economic benefits to the public health system. Legislative efforts under Bill 969/26, authored by Deputy Fausto Jr., also aim to expand healthcare access to rural, riverside, and indigenous communities through the use of mobile units. This push for modernization coincides with recognition of scientific contributions to the field, such as scientist Luisa Lina Villa receiving the Octavio Frias de Oliveira Prize for her research establishing the link between HPV and various cancers. Concurrently, the public health system in the Distrito Federal has detailed a comprehensive breast cancer early-detection pathway. This system offers free mammograms for women aged 40 to 75 through various hospitals and the ‘Peito Aberto’ partnership. The pathway includes fast-tracking patients with abnormalities to mastologists with an average wait of less than 30 days, followed by immediate treatment for confirmed cases. ~~Together, these developments reflect a national push to modernize cancer screening and improve early diagnosis across multiple cancer types.~~

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.